Summary
ADV Pharma is a financial institution. The bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €2.5m and a net result of €556,412. Equity has been growing by about 13% per year since 2018. Its solvency ranks better than 36% of 6,692 sector peers (NACE 64, financial year 2025). The company has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
Source: KBO- Status
- Active since 14-02-2011 Normal situation
- Activity
- Activities of holding companies NACE 64210and 1 other
- Establishment unit
- 2.196.610.035 6230 Pont-à-Celles, since 14-02-2011
- Financial year end
- 31 December
- Peppol
- Reachable since 09-12-2025
Board and ownership
Board
- FJA SNCDirector · since 01-07-2014
- MCGD SNCDirector · since 01-07-2014
- Holdings
- Shares in 4 companies including BAUPHAR and La Pharmacie de Saintes
Financial position
Financial institution: outside the modelBankruptcy probability: sector outside the model
Annual accounts 2025
- Profit
- €556,412
- ▼ 23.7%
- Equity
- €2.5m
- ▼ 6.8%
- Total assets
- €7.3m
- ▲ 25.7%
SignalsneutralLatest accounts filed on timeShow the evidence
Checked score
Outside the general model
Model not applicable to financial institutions
The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
1 signal.
neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
28 days early
2024
17 days early
2023
1 day early
2022
17 days early
2021
4 days early
2020
6 days late
2019
8 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 10 days before the deadline. In the sector (NACE 64), the median for financial year 2024 was 14 days before the deadline, and 28% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 14 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
- Positive: Higher net result than 89% of companies in financial servicessector median €51,535 · 6,691 companies €556,412 View
- Positive: 8 profitable years in a rowprofit 2025: €556,412 8 years View
- Heads a groupcompanies controlled 4 View
- Positive: Filed on time since financial year 2021accounts within the deadline every year 5 years View
Recent changes
- · Gazette deed General meeting · Director reappointment
- · Gazette deed Shareholding · General meeting
- · Gazette deed Incorporation
Companies linked to ADV Pharma
Comparable companies
These companies have the same main activity as ADV Pharma: activities of holding companies (NACE 64210). They are comparable in size and age: total assets between €6.1m and €8m, founded between 2010 and 2012.
| Company | Total assets | Gross margin |
|---|---|---|
| ADV Pharma Rebecq | €7.3m | €0.4m |
| PATCOR De Haan | €7.1m | €0.4m |
| BBC Parts Laarne | €7.5m | €0.4m |
| GUILIMMO Brasschaat | €7.0m | €0.4m |
| KJT Consultancy Zonhoven | €8.0m | €0.4m |
| MARC DESSEIN Kortrijk | €6.1m | €0.5m |
| MKG Beringen | €6.3m | €0.5m |
Key facts about ADV Pharma
- What is the company number of ADV Pharma?
- The company number of ADV Pharma is 0833.723.215. The VAT number is the same number with BE in front: BE 0833.723.215.
- Where is ADV Pharma based?
- The registered office is at Route de Quenast 15, 1430 Rebecq.Company details
- What does ADV Pharma do?
- According to the KBO register, the main activity is activities of holding companies (NACE 64210).
- What is the legal form of ADV Pharma?
- The legal form of ADV Pharma is Private limited company (pre-2019) (BVBA).
- When was ADV Pharma founded?
- ADV Pharma was founded on 14-02-2011.
- Is ADV Pharma still active?
- Yes, ADV Pharma is an active enterprise in the KBO register.
- What is the turnover of ADV Pharma?
- The turnover in financial year 2025 is ≈ €560,000. This figure is estimated from the gross margin of €426,155 and 34 comparable companies (NACE 64210). It probably lies between €470,000 and €880,000.Financials
- Is ADV Pharma profitable?
- In financial year 2025, ADV Pharma made a profit of €556,412.
- Where can I find the annual accounts of ADV Pharma?
- ADV Pharma filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ADV Pharma due?
- ADV Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See what changed in the latest annual accounts.What changed See this company's board, registered office and name on a given date.Company as of a date
See how customers, suppliers and banks see your own company and what to improve first.